Skip to main content
In stock | Cellular Therapy (CAR-T)

Zevorcabtagene Autoleucel

Oncology Type Hematologic (Multiple Myeloma)
Drug Class / Mechanism Autologous Anti-BCMA CAR-T Cell Therapy
No Image
Description

Zevorcabtagene Autoleucel is classified as an Autologous Anti-BCMA CAR-T Cell Therapy, sourced for use within our Cellular Therapy (CAR-T) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Cellular Therapy (CAR-T)
Oncology Type Hematologic (Multiple Myeloma)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3